{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-020207","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.033591+00:00","generated_at":"2026-06-24T06:03:26.336302+00:00","sec_items":["2.03","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Arcutis gets FDA approval for ZORYVE (roflumilast) cream 0.3% for plaque psoriasis; draws $125M in debt","bullets":["FDA approved ZORYVE (roflumilast) cream 0.3% for plaque psoriasis, including intertriginous areas, in patients 12+.","First and only topical PDE4 inhibitor approved for plaque psoriasis; once-daily, steroid-free, no duration limit.","Commencing $125M drawdown of Tranche B term loans from SLR Investment Corp. to fund launch and pipeline.","Product expected to be available via wholesalers and dermatology pharmacies by mid-August 2022.","DERMIS-1/2 Phase 3 trials: 42% and 37% IGA success at Week 8 (P<0.0001); itch reduction as early as Week 2."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-020207","json":"https://secwatch.observer/filing/0001628280-22-020207.json","markdown":"https://secwatch.observer/filing/0001628280-22-020207.md","text":"https://secwatch.observer/filing/0001628280-22-020207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000162828022020207/0001628280-22-020207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000162828022020207/arqt-20220729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:03:26.336302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}